文献速递多重用药老年综合评估

利益相关者对问题性多重用药及处方级联的认知与态度:一项定性研究

Stakeholder perceptions of and attitudes towards problematic polypharmacy and prescribing cascades: a qualitative study.
PubMed 文献 · Age Ageing · 2024-01-01

本研究通过一对一半结构化访谈,了解患者、照护者、全科医生、药师、医院医生、专业组织代表和政策制定者对问题性多重用药及处方级联的看法。结论认为多重用药达到一定深度后,新症状由现有药物引起的风险变得不可计算,若无伤害则避免调整药物,但出院后药物重整迫使做出处方决策且被视为高风险活动。

要点

  • 利益相关者认为多重用药达到一定深度后,新症状由现有药物导致的风险不可计算。
  • 在无伤害情况下,医护人员倾向于避免调整药物。
  • 出院后药物重整迫使处方决策,被利益相关者视为高风险活动。

核心结论

  • 利益相关者认为多重用药达到一定深度后,新症状由现有药物引起的风险变得不可计算,因此在无伤害时避免调整药物。
  • 出院后药物重整迫使做出处方决策,并被利益相关者视为高风险活动。

研究设计与样本

  • 定性研究,采用一对一半结构化访谈,对预设的关键利益相关者群体进行访谈。
  • 采用归纳性主题分析。

主要发现

  • 识别出三个主要主题:药物不良反应与处方级联——必要之恶;平衡风险获益的临界点;药物重整的雷区。
  • 医护人员担心发生药物不良反应会负面影响患者对医生的信心,而患者将药物不良反应视为不可预测的风险。
  • 多重用药背景下的处方决策复杂性使平衡风险获益临界点具有挑战性,导致医护人员避免调整药物。
  • 利益相关者(包括患者和照护者)因系统性沟通缺陷而将药物重整视为危险活动。

关键数值与推荐

  • 问题性多重用药定义为处方五种或以上可能不适当的药物。
  • 处方级联指药物不良反应被误认为新症状而导致启用新药物。

临床怎么用

  • 老年医学科医生应关注多重用药达到一定深度后新症状可能由现有药物引起,避免在无伤害时常规调整药物。
  • 出院后药物重整被视为高风险活动,需注意系统性沟通缺陷并谨慎进行处方决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Problematic polypharmacy is the prescribing of five or more medications potentially inappropriately. Unintentional prescribing cascades represent an under-researched aspect of problematic polypharmacy and occur when an adverse drug reaction (ADR) is misinterpreted as a new symptom resulting in the initiation of a new medication. The aim of this study was to elicit key stakeholders' perceptions of and attitudes towards problematic polypharmacy, with a focus on prescribing cascades. METHODS: qualitative one-to-one semi-structured interviews were conducted with predefined key stakeholder groups. Inductive thematic analysis was employed. RESULTS: Thirty-one stakeholders were interviewed: six patients, two carers, seven general practitioners, eight pharmacists, four hospital doctors, two professional organisation representatives and two policymakers. Three main themes were identified: (i) ADRs and prescribing cascades-a necessary evil. Healthcare professionals (HCPs) expressed concern that experiencing an ADR would negatively impact patients' confidence in their doctor. However, patients viewed ADRs pragmatically as an unpredictable risk. (ii) Balancing the risk/benefit tipping point. The complexity of prescribing decisions in the context of polypharmacy made balancing this tipping point challenging. Consequently, HCPs avoided medication changes. (iii) The minefield of medication reconciliation. Stakeholders, including patients and carers, viewed medication reconciliation as a perilous activity due to systemic communication deficits. CONCLUSION: Stakeholders believed that at a certain depth of polypharmacy, the risk that a new symptom is being caused by an existing medication becomes incalculable. Therefore, in the absence of harm, medication changes were avoided. However, medication reconciliation post hospital discharge compelled prescribing decisions and was seen as a high-risk activity by stakeholders.

来源:Age Ageing,查看原文。版权归原作者所有。

引用

  1. Jennings AA, Doherty AS, Clyne B, et al. Stakeholder perceptions of and attitudes towards problematic polypharmacy and prescribing cascades: a qualitative study. Age Ageing. 2024. PMID: 38851215. doi:10.1093/ageing/afae116

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。